ID

27361

Beschrijving

Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

Trefwoorden

Versies (3)
  1. 09-11-17 09-11-17 -
  2. 09-11-17 09-11-17 -
  3. 26-11-17 26-11-17 -
Houder van rechten

GlaxoSmithKline

Geüploaded op

9 november 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Screen visit GSK study Prostatic neoplasms NCT00883909

Engels

Screen visit GSK study Prostatic neoplasms NCT00883909

1 Formulieren  
Administrative data
Beschrijving

Administrative data

Session number
Beschrijving

Session number

Datatype

integer

Subject number
Beschrijving

Subject number

Datatype

text

Previous Subject number
Beschrijving

Previous Subject number

Date of assessment
Beschrijving

Date of assessment

Datatype

date

Previous Subject Number from the REDUCE (ARI40006) Study
Beschrijving

Previous Subject Number

Datatype

text

Inclusion / Exclusion Criteria Worksheet
Beschrijving

Inclusion / Exclusion Criteria Worksheet

Inclusion criteria: 1. Has the subject signed and dated a written informed consent?
Beschrijving

If the INCLUSION CRITERIA question is answered NO, this subject must NOT enter this study.

Datatype

text

Inclusion criteria: 2. Did the subject participate in the REDUCE Study and meet the eligibility criteria for Part A, the 2 Year Observational Follow-Up Study and/or Part B, the Prostate Biopsy Tissue Study?
Beschrijving

If the INCLUSION CRITERIA question is answered NO, this subject must NOT enter this study.

Datatype

text

Exclusion criteria (Part A only): 1. Is the subject unable/unwilling to participate in the Follow-Up Study telephone calls?
Beschrijving

If any EXCLUSION CRITERIA question is answered YES, this subject must NOT enter this study.

Datatype

text

Inclusion/Exclusion Criteria
Beschrijving

Inclusion/Exclusion Criteria

Did the subject meet all entry criteria (i.e., All "YES" answers for inclusion criteria, all "NO" answers for exclusion criteria)?
Beschrijving

See INCLUSION / EXCLUSION CRITERIA WORKSHEET.

Datatype

text

Check all boxes that represent a violation of the inclusion / exclusion criteria: Inclusion criteria 1.
Beschrijving

informed consent violation

Datatype

boolean

Check all boxes that represent a violation of the inclusion / exclusion criteria: Inclusion criteria 2.
Beschrijving

eligibility criteria violation

Datatype

boolean

Check all boxes that represent a violation of the inclusion / exclusion criteria: Exclusion criteria 1.
Beschrijving

participation in Follow-Up Study telephone calls violation

Datatype

boolean

Eligibility Criteria
Beschrijving

Eligibility Criteria

1. Part A: Any subject who has participated in the REDUCE Study and meets one of the following eligibility criteria for Part A, 2 Year Observational Follow-Up Study.
Beschrijving

eligibility part A

Datatype

boolean

If Part A is checked, indicate which one of the following Part A Eligibility Criteria the subject meets:
Beschrijving

Part A Eligibility Criteria

Datatype

text

2. Part B: Any subject who was diagnosed with prostate cancer based on a prostate biopsy during participation in the REDUCE Study, regardless of when their REDUCE study participation ended.
Beschrijving

eligibility part B

Datatype

boolean

Investigator’s Statement
Beschrijving

Investigator’s Statement

Date
Beschrijving

Sign and date this page after all relevant Screening CRF pages, including outstanding test results, are completed. Check that the date of signature is on or after the completion of the Screening Visit.

Datatype

date

Investigator’s Signature
Beschrijving

Sign and date this page after all relevant Screening CRF pages, including outstanding test results, are completed. "I confirm that I have carefully examined all entries on the Screening Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, correct as of the date."

Datatype

text

Investigator’s Name - Print
Beschrijving

Investigator’s Name

Datatype

text

Terug naar het begin van de pagina

Similar models

Screen visit GSK study Prostatic neoplasms NCT00883909

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Administrative data
Session number
Item
Session number
integer
Subject number
Item
Subject number
text
Item Group
Previous Subject number
Date of assessment
Item
Date of assessment
date
Previous Subject Number
Item
Previous Subject Number from the REDUCE (ARI40006) Study
text
Item Group
Inclusion / Exclusion Criteria Worksheet
Item
Inclusion criteria: 1. Has the subject signed and dated a written informed consent?
text
informed consent
Code List
Inclusion criteria: 1. Has the subject signed and dated a written informed consent?
CL Item
Yes (Y)
CL Item
No (N)
Item
Inclusion criteria: 2. Did the subject participate in the REDUCE Study and meet the eligibility criteria for Part A, the 2 Year Observational Follow-Up Study and/or Part B, the Prostate Biopsy Tissue Study?
text
informed consent
Code List
Inclusion criteria: 2. Did the subject participate in the REDUCE Study and meet the eligibility criteria for Part A, the 2 Year Observational Follow-Up Study and/or Part B, the Prostate Biopsy Tissue Study?
CL Item
Yes (Y)
CL Item
No (N)
Item
Exclusion criteria (Part A only): 1. Is the subject unable/unwilling to participate in the Follow-Up Study telephone calls?
text
informed consent
Code List
Exclusion criteria (Part A only): 1. Is the subject unable/unwilling to participate in the Follow-Up Study telephone calls?
CL Item
Yes (Y)
CL Item
No (N)
Item Group
Inclusion/Exclusion Criteria
Item
Did the subject meet all entry criteria (i.e., All "YES" answers for inclusion criteria, all "NO" answers for exclusion criteria)?
text
informed consent
Code List
Did the subject meet all entry criteria (i.e., All "YES" answers for inclusion criteria, all "NO" answers for exclusion criteria)?
CL Item
Yes (Y)
CL Item
No (N)
informed consent violation
Item
Check all boxes that represent a violation of the inclusion / exclusion criteria: Inclusion criteria 1.
boolean
eligibility criteria violation
Item
Check all boxes that represent a violation of the inclusion / exclusion criteria: Inclusion criteria 2.
boolean
participation in Follow-Up Study telephone calls violation
Item
Check all boxes that represent a violation of the inclusion / exclusion criteria: Exclusion criteria 1.
boolean
Item Group
Eligibility Criteria
eligibility part A
Item
1. Part A: Any subject who has participated in the REDUCE Study and meets one of the following eligibility criteria for Part A, 2 Year Observational Follow-Up Study.
boolean
Item
If Part A is checked, indicate which one of the following Part A Eligibility Criteria the subject meets:
text
Part A Eligibility Criteria
Code List
If Part A is checked, indicate which one of the following Part A Eligibility Criteria the subject meets:
CL Item
Completed 4 years on Investigational Product through the REDUCE 4-Year Study Visit (Visit 10). (a)
CL Item
Was diagnosed with prostate cancer during the REDUCE study, discontinued Investigational Product but participated in REDUCE prostate cancer follow-up visits through the 4-Year Study Visit (Visit 10P). (b)
CL Item
Withdrew from REDUCE study visit participation and Investigational Product (for any reasons) but participated in REDUCE follow-up phone calls every 6 months through the 4 Year Phone Call. (c)
eligibility part B
Item
2. Part B: Any subject who was diagnosed with prostate cancer based on a prostate biopsy during participation in the REDUCE Study, regardless of when their REDUCE study participation ended.
boolean
Item Group
Investigator’s Statement
Date
Item
Date
date
Investigator’s Signature
Item
Investigator’s Signature
text
Investigator’s Name
Item
Investigator’s Name - Print
text
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial